Zinc-α2-glycoprotein: A new biomarker of breast cancer?

Anticancer Research

Volumn 30, Issue 7, 2010, Pages 2919-2925

  Dubois, Virginie ^a,b   Delort, L ^a,b   Mishellany, F ^c   Jarde, T ^a,b   Billard, H ^a,b   Lequeux, C ^d   Damour, O ^d   Penault Llorca, F ^c   Vasson, M P ^b,c,e   Caldefie Chezet, F ^a,b,e  

^a Laboratoire SVFp   (France)

^b UNIVERSITÉ CLERMONT AUVERGNE   (France)

^c CENTRE JEAN PERRIN   (France)

^d EDOUARD HERRIOT HOSPITAL   (France)

^e Région Lyon Auvergne Rhône Alpes ^*  (France)

Author keywords

Adipokine; Adiponectin; Apoptosis; Biomarker; Breast cancer; Leptin; Zinc 2 glycoprotein

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN RECEPTOR; BIOLOGICAL MARKER; ESTROGEN RECEPTOR; KI 67 ANTIGEN; LEPTIN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN BAX; PROTEIN BCL 2; UNCLASSIFIED DRUG; ZINC ALPHA 2 GLYCOPROTEIN; ADIPONECTIN; ADIPONECTIN, HUMAN; AZGP1 PROTEIN, HUMAN; BAX PROTEIN, HUMAN; CARRIER PROTEIN; GLYCOPROTEIN; LEPTIN; TUMOR MARKER;

ADULT; AGED; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; EPITHELIUM; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; BIOSYNTHESIS; BREAST TUMOR; CARCINOMA IN SITU; CASE CONTROL STUDY; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; PHYSIOLOGY;

ADIPONECTIN; ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; CARRIER PROTEINS; CASE-CONTROL STUDIES; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; LEPTIN; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR MARKERS, BIOLOGICAL;

EID: 77955788639     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Calle EE and Kaaks R: Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nature Rev 4: 579-591, 2004.
2. Chu SY, Lee NC, Wingo PA, Senie RT, Greenberg RS and Peterson HB: The relationship between body mass and breast cancer among women enrolled in the Cancer and Steroid Hormone Study. J Clin Epidemiol 44: 1197-1206, 1991.
3. Lahmann PH, Hoffmann K, Allen N, van Gils CH, Khaw KT, Tehard B, Berrino F, Tjonneland A, Bigaard J, Olsen A, Overvad K, Clavel-Chapelon F, Nagel G, Boeing H, Trichopoulos D, Economou G, Bellos G, Palli D, Tumino R, Panico S, Sacerdote C, Krogh V, Peeters PH, Bueno-de-Mesquita HB, Lund E, Ardanaz E, Amiano P, Pera G, Quirós JR, Martínez C, Tormo MJ, Wirfált E, Berglund G, Hallmans G, Key TJ, Reeves G, Bingham S, Norat T, Biessy C, Kaaks R and Riboli E: Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 111: 762-771, 2004. (Pubitemid 39062901)
4. Key TJ, Allen NE, Verkasalo PK and Banks E: Energy balance and cancer: the role of sex hormones. The Proc Nutr Soc 60: 81-89, 2001.
5. Fain JN, Madan AK, Hiler ML, Cheema P and Bahouth SW: Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 145: 2273-2282, 2004. (Pubitemid 38535056)
6. Dizdar O and Alyamac E: Obesity: an endocrine tumor? Med Hypoth 63: 790-792, 2004.
7. Caldefie-Chezet F, Damez M, de Latour M, Konska G, Mishellani F, Fusillier C, Guerry M, Penault-Llorca F, Guillot J and Vasson MP: Leptin: a proliferative factor for breast cancer? Study on human ductal carcinoma. Biochem Biophy Res Comm 334: 737-741, 2005.
8. Jarde T, Caldefie-Chezet F, Damez M, Mishellany F, Penault-Llorca F, Guillot J and Vasson MP: Leptin and leptin receptor involvement in cancer development: a study on human primary breast carcinoma. Oncology Rep 19: 905-911, 2008. (Pubitemid 351802658)
9. Jarde T, Caldefie-Chezet F, Damez M, Mishellany F, Perrone D, Penault-Llorca F, Guillot J and Vasson MP: Adiponectin and leptin expression in primary ductal breast cancer and in adjacent healthy epithelial and myoepithelial tissue. Histopathology 53: 484-487, 2008.
10. Filigheddu N, Cutrupi S, Porporato PE, Riboni F, Baldanzi G, Chianale F, Fortina E, Piantanida P, De Bortoli M, Vacca G, Graziani A and Surico N: Diacylglycerol kinase is required for HGF-induced invasiveness and anchorage-independent growth of MDA-MB-231 breast cancer cells. Anticancer Res 27: 1489-1492, 2007.
11. Kang JH, Yu BY and Youn DS: Relationship of serum adiponectin and resistin levels with breast cancer risk. J Kor Med Sci 22: 117-121, 2007.
12. Sorli SC, Le Gonidec S, Knibiehler B and Audigier Y: Apelin is a potent activator of tumor neoangiogenesis. Oncogene 26: 7692-7699, 2007. (Pubitemid 350224216)
13. Selim AA, El-Ayat G and Wells CA: Immunohistochemical localization of gross cystic disease fluid protein-15, -24 and -44 in ductal carcinoma in situ of the breast: relationship to the degree of differentiation. Histopathology 39: 198-202, 2001.
14. Hassan MI, Waheed A, Yadav S, Singh TP and Ahmad F: Zinc alpha 2-glycoprotein: a multidisciplinary protein. Mol Cancer Res 6: 892-906, 2008.
15. Bing C, Bao Y, Jenkins J, Sanders P, Manieri M, Cinti S, Tisdale MJ and Trayhurn P: Zinc-alpha2-glycoprotein, a lipid mobilizing factor, is expressed in adipocytes and is up-regulated in mice with cancer cachexia. Proc Natl Acad Sc USA 101: 2500-2505, 2004. (Pubitemid 38269340)
16. Descazeaud A, de Ia Taille A, Allory Y, Faucon H, Salomon L, Bismar T, Kim R, Hofer MD, Chopin D, Abbou CC and Rubin MA: Characterization of ZAG protein expression in prostate cancer using a semi-automated microscope system. Prostate 66: 1037-1043, 2006.
17. Burgi W and Schmid K: Preparation and properties of Zn-alpha 2-glycoprotein of normal human plasma. J Bio Chem 236: 1066-1074, 1961.
18. Skipworth RJ, Stewart GD, Bhana M, Christie J, Sturgeon CM, Guttridge DC, Crenshaw AD, Fearon KC and Ross JA: Mass spectrometric detection of candidate protein biomarkers of cancer cachexia in human urine. Int J Oncol 36: 973-82, 2010.
19. Diez-Itza I, Sanchez LM, Allende MT, Vizoso F, Ruibal A and Lopez-Otin C: Zn-alpha 2-glycoprotein levels in breast cancer cytosols and correlation with clinical, histological and biochemical parameters. Eur J Cancer 29A: 1256-1260, 1993. (Pubitemid 23169892)
20. Bao Y, Bing C, Hunter L, Jenkins JR, Wabitsch M and Trayhurn P: Zinc-alpha2-glycoprotein, a lipid mobilizing factor, is expressed and secreted by human (SGBS) adipocytes. FEBS Lett 579: 41-47, 2005. (Pubitemid 40023371)
21. Marrades MP, Martinez JA and Moreno-Aliaga MJ: ZAG, a lipid mobilizing adipokine, is down-regulated in human obesity. J Physiol Biochem 64: 61-66, 2008.
22. Mracek T, Gao D, Tzanavari T, Bao Y, Xiao X, Stocker C, Trayhurn P and Bing C: Down-regulation of zinc-{alpha}2-glycoprotein in adipose tissue and liver of obese ob/ob mice and by tumor necrosis factor-alpha in adipocytes. J Endocrinol 204: 165-72, 2010.
23. Selva DM, Lecube A, Hernández C, Baena JA, Fort JM and Simó R: Lower zinc-alpha2-glycoprotein production by adipose tissue and liver in obese patients unrelated to insulin resistance. J Clin Endocrinol Metab 94: 4499-507, 2009.
24. Russell ST, Zimmerman TP, Domin BA and Tisdale MJ: Induction of lipolysis in vitro and loss of body fat in vivo by zinc-alpha2-glycoprotein. Biochim Biophys Acta 1636: 59-68, 2004.
25. Bing C and Trayhurn P: New insights into adipose tissue atrophy in cancer cachexia. Proc Nutr Soc 68: 385-92, 2009.
26. Sanchez LM, Vizoso F, Diez-Itza I and Lopez-Otin C: Identification of the major protein components in breast secretions from women with benign and malignant breast diseases. Cancer Res 52: 95-100, 1992.
27. Byerley LO, Lee SH, Redmann S, Culberson C, Clemens M and Lively MO: Evidence for a novel serum factor distinct from zinc alpha-2 glycoprotein that promotes body fat loss early in the development of cachexia. Nutr Cancer 62: 484-94, 2010.
28. Kamoshida S, Watanabe K, Suzuki M, Mizutani Y, Sakamoto K, Sugimoto Y, Oka T, Fukushima M, Tsutsumi Y: Expression of cancer cachexia-related factors in human cancer xenografts: an immunohistochemical analysis. Biomedical Res (Tokyo, Japan) 27: 275-281, 2006.
29. Rehman S, Crow J and Revell PA: Bax protein expression in DCIS of the breast in relation to invasive ductal carcinoma and other molecular markers. Pathol Oncol Res 6: 256-263, 2000. (Pubitemid 32167618)
30. Veronese S, Mauri FA, Caffo O, Scaioli M, Aldovini D, Perrone G, Galligioni E, Doglioni C, Dalla Palma P and Barbareschi M: Bax immunohistochemical expression in breast carcinoma: a study with long-term follow-up. Int J Cancer 79: 13-18, 1998.
31. Penault-Llorca F, Cayre A, Bouchet Mishellany F, Amat S, Feillel V, Le Bouedec G, Ferriere JP, De Latour M and Chollet P: Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome. Int J Oncol 22: 1319-1325, 2003.
32. Elston CW and Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403-410, 1991.
33. Baccouche S, Daoud J, Frikha M, Mokdad-Gargouri R, Gargouri A and Jlidi R: Immunohistochemical status of p53, MDM2, bcl2, bax, and ER in invasive ductal breast carcinoma in Tunisian patients. Ann NY Acad Sci 1010: 752-763, 2003. (Pubitemid 38265077)